Bristol-myers Squibb Compnay

Bristol-myers Company

Universitéde Montreal

Bristol-myers Squibb Holdings Ireland

Alain Martel

Carol Bachand

Makonen Belema

Edward H Ruediger

Van N Nguyen

Daniel H Deon

Nicholas A Meanwell

Lawrence G Hamann

Andrew Charles Good

David R Langley

Lawrence B Snyder

Omar D Lopez

Jeffrey Lee Romine

Denis R St Laurent

Jason T Goodrich

Clint A James

Fukang Yang

Rico Lavoie

Gan Wang

Marcel Menard

Anne Marinier

Jacques Banville

Jean-Paul Daris

R Michael Lawrence

Shoshana L Posy

Alejandro A Aruffo

Michael Matthew Miller

Stephan Roy

Francois Tremblay

François Tremblay

Jacques Corbeil

Anna M Ericsson

John E Starrett, Jr

John J Wright

Eldon Scott Priestley

Yuping Qiu

Neelakantan Balasubramanian

Francis Beaulieu

Fred Christopher Zusi

Yunhui Zhang

Marc Gagnon

Roger Remillard

Amy Mae Bunker

Carl Ouellet

Kenneth M Tramposch

Dietmar A Seiffert

Pancras C Wong

Peter R Reczek

Xuejie Yang

Julia Guy

Gilles Bouthillier

Xina Nair

Jean-François Lavallée

Christopher Zusi

Belema Makonen

The present invention provides compounds of Formula I: wherein Y, AA, W, RR, R, R, R, R, X, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders. 

Heterocyclic compounds as inhibitors of platelet aggregation

The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, R, R, R, R, X, Xand s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments. 

Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present invention provides thiazole compounds of Formula I wherein X, Y, Z, X, X, X, X, X, R, R, R, R, R, R, and W, are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Imidazotriazine and imidazodiazine compounds

The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R, R, R, R, R, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders. 

Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

Growing community of inventors

Delson, Canada

Alain Martel